Commentary: SARS-CoV-2 vaccines and cancer patients

Ann Oncol. 2021 Apr;32(4):569-571. doi: 10.1016/j.annonc.2020.12.019. Epub 2021 Jan 12.

Authors

C Corti¹, G Curigliano²

Affiliations

¹ Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.
² Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral
COVID-19 Vaccines
COVID-19*
Humans
Neoplasms* / therapy
SARS-CoV-2

Substances

Antibodies, Viral
COVID-19 Vaccines